Third generation Enzyme ImmunoAssay (ELISA) for the qualitative determination of IgG antibodies to Hepatitis E Virus in human plasma and sera. The kit may be used for the screening of blood units and the follow-up of HEV-infected patients. For “in vitro” diagnostic use only.
Introduction
Hepatitis E Virus or HEV is a recently discovered agent of enterically transmitted viral hepatitis. HEV is an unenveloped single-strand RNA virus structurally similar to Calicivirus and is found in the stool of infected patients.
HEV is a serious problem in many developing countries and its first outbreak was reported in 1955 in New Delhi, India. Hepatitis E has never been associated with chronic infection; however a high case-fatality rate has been found among pregnant women.
The cloning and sequencing of HEV genome have lead to the development of serological tests for the detection of anti HEV antibodies.
These tests are based on synthetic immunodominant antigens derived from conservative regions of the virus.
Principle of the Method
Microplates are coated with HEV-specific synthetic antigens encoding for conservative and immunodominant determinants derived from ORF2 and ORF3 of all the 4 subtypes.
The solid phase is first treated with the diluted sample and anti HEV IgG are captured, if present, by the antigens.
After washing out all the other components of the sample, in the 2nd incubation bound anti-HEV IgG are detected by the addition of polyclonal specific anti hIgG antibodies, labelled with peroxidase (HRP).
The enzyme captured on the solid phase, acting on the substrate mixture,